PharmiWeb.com - Global Pharma News & Resources

General - Press Releases

Date Title Company
10-Nov-2023 Takeda erhält US-Zulassung der FDA für FRUZAQLA™ (Fruquintinib) zur Behandlung von metastasiertem Dickdarmkrebs Businesswire
10-Nov-2023 Cencora Announces Common Share Repurchase From Walgreens Boots Alliance Businesswire
10-Nov-2023 OmniAb Highlights OmnidAb™ Launch and its Expanding Drug Discovery Platform at Today’s Research & Technology Virtual Event Businesswire
10-Nov-2023 Thermo Fisher Scientific Declares Quarterly Dividend Businesswire
10-Nov-2023 Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results Businesswire
10-Nov-2023 Marinus Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) Businesswire
10-Nov-2023 Takeda obtient l’approbation de la FDA des États-Unis pour le FRUZAQLA™ (fruquintinib) dans le traitement du cancer colorectal métastatique déjà traité Businesswire
10-Nov-2023 Model N Announces Fourth Quarter and Fiscal Year 2023 Financial Results Businesswire
10-Nov-2023 Aura Biosciences Reports Third Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Businesswire
10-Nov-2023 MEI Pharma Reports First Quarter Fiscal Year 2024 Results and Operational Highlights Businesswire
10-Nov-2023 Omeros Corporation Reports Third Quarter 2023 Financial Results Businesswire
10-Nov-2023 Akili Reports Third Quarter 2023 Financial Results and Provides Business Update Businesswire
10-Nov-2023 BeiGene Continues Global Growth with Third Quarter 2023 Financial Results and Business Updates Businesswire
10-Nov-2023 Lineage Cell Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Businesswire
09-Nov-2023 Takeda’s ADZYNMA (ADAMTS13, recombinant-krhn) Approved by U.S. FDA as the First and Only Recombinant ADAMTS13 Enzyme Replacement Therapy for the Treatment of Congenital Thrombotic Thrombocytopenic Purpura (cTTP) Businesswire
09-Nov-2023 A Takeda recebe aprovação da FDA dos EUA para FRUZAQLA™ (fruquintinibe) para câncer colorretal metastático previamente tratado Businesswire
09-Nov-2023 Scynexis, Inc. (SCYX) Investor Notice: Robbins LLP Reminds Investors of Class Action Filed Against Scynexis, Inc. Businesswire
09-Nov-2023 MaaT Pharma Provides Third Quarter 2023 Business Update and Reports Financial Results Businesswire
09-Nov-2023 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of PetMed Express, Inc. (PETS) on Behalf of Investors Businesswire
09-Nov-2023 Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Paycom Software, Inc. (PAYC) on Behalf of Investors Businesswire